BOLT (Bolt Biotherapeutics) LT-Debt-to-Total-Asset: 0.40 (As of Mar. 2026)

What is Bolt Biotherapeutics LT-Debt-to-Total-Asset?

Bolt Biotherapeutics BOLT -11.25% 55 LT-Debt-to-Total-Asset is 0.40 as of Mar. 2026. GuruFocus rates BOLT with a GF Score™ of 55/100 and a GF Value™ of $9.03 (Possible Value Trap). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bolt Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.40.

Bolt Biotherapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.26) to Mar. 2026 (0.40). It may suggest that Bolt Biotherapeutics is progressively becoming more dependent on debt to grow their business.

Bolt Biotherapeutics (NAS:BOLT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bolt Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Bolt Biotherapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics LT-Debt-to-Total-Asset Chart

Bolt Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.09

0.11

0.23

0.36

Bolt Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.26	0.29	0.32	0.36	0.40

55GF Score

Bolt Biotherapeutics Inc BOLT

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bolt Biotherapeutics LT-Debt-to-Total-Asset Calculation

Bolt Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	20.132	/	56.748
	=	0.35

Bolt Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	19.352	/	48.027
	=	0.40

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.40 mean?

Bolt Biotherapeutics (BOLT) has a LT-Debt-to-Total-Asset of 0.40 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bolt Biotherapeutics and its competitors.

Is Bolt Biotherapeutics' LT-Debt-to-Total-Asset too high?

Bolt Biotherapeutics' current LT-Debt-to-Total-Asset is 0.40. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Bolt Biotherapeutics' LT-Debt-to-Total-Asset compare to AIM and ERNA?

Bolt Biotherapeutics' LT-Debt-to-Total-Asset of 0.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current LT-Debt-to-Total-Asset is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bolt Biotherapeutics stock overvalued right now?

Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.03, compared to a current price of $3.91 — trading 56.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.40. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current LT-Debt-to-Total-Asset is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of $3.91 is trading 56.8% below its estimated GF Value™ of $9.03. GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.

Key valuation signals for BOLT:

LT-Debt-to-Total-Asset: 0.40
GF Value™: $9.03 vs. price of $3.91 (56.8% below fair value)
GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies AIM ERNA RVPH PMCB SYBX ASBP CURX IMNN KAPA BRTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063

Website https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

55GF Score

Get the complete analysis for BOLT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.91

Price

$9.03

GF Value

View BOLT Analysis

See LT-Debt-to-Total-Asset data for all stocks →